Mevastatin, HMG-CoA reductase inhibitor (ab120652)
Key features and details
- Potent HMG-CoA reductase inhibitor
- CAS Number: 73573-88-3
- Purity: > 98%
- Soluble in ethanol to 10 mM and DMSO to 100 mM
- Form / State: Solid
- Source: Synthetic
製品の概要
-
製品名
Mevastatin, HMG-CoA reductase inhibitor -
製品の詳細
Potent HMG-CoA reductase inhibitor -
別名
- Compactin
-
生理活性の詳細
Potent HMG-CoA reductase inhibitor. Proapoptotic, able to arrest cells in G1 by down-regulation of CDK4, CDK6 and cyclin D1 and up-regulation of p21 and p27.
-
精製度
> 98% -
CAS 番号
73573-88-3 -
構造式
製品の特性
-
体系名
(2S)-2-Methyl-(1S,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-7-methyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl butanoate -
分子量
390.52 -
分子式
C23H34O5 -
PubChem 登録番号
64715 -
保存方法
Store at +4°C. Store under desiccating conditions. The product can be stored for up to 12 months. -
溶解性
Soluble in ethanol to 10 mM and DMSO to 100 mM -
使用に関する注意
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Toxic, refer to SDS for further information.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
由来
Synthetic
-
研究分野
- Metabolism
- Pathways and Processes
- Metabolic signaling pathways
- Nucleotide metabolism
- Molecular processes
- Mitochondrial transcription
- Metabolism
- Pathways and Processes
- Metabolic signaling pathways
- Lipid and lipoprotein metabolism
- Lipid metabolism
- Metabolism
- Pathways and Processes
- Metabolic signaling pathways
- Lipid and lipoprotein metabolism
- Cholesterol Metabolism
- Metabolism
- Pathways and Processes
- Metabolic signaling pathways
- Lipid and lipoprotein metabolism
- Lipoprotein metabolism
- Metabolism
- Pathways and Processes
- Metabolic signaling pathways
- Energy transfer pathways
- Energy Metabolism
- Biochemicals
- Research Area
- Pain & inflammation
- Signaling
- Lipid signaling
- HMG-CoA reductase
- Inhibitors
- Biochemicals
- Research Area
- Alzheimer's Disease
- Signaling
- Lipid signaling
- HMG-CoA reductase
- Inhibitors
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab120652の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
Functional Studies |
Use at an assay dependent concentration.
|
特記事項 |
---|
Functional Studies
Use at an assay dependent concentration. |
画像
-
2D chemical structure image of ab120652, Mevastatin, HMG-CoA reductase inhibitor
-
ab90529 staining cytochrome C in HepG2 cells treated with mevastatin (ab120652), by ICC/IF. Increase of cytochrome C expression correlates with increased concentration of mevastatin, as described in literature.
The cells were incubated at 37°C for 4 hours in media containing different concentrations of ab120652 (mevastatin) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab90529 (1 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.
プロトコール
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
参考文献 (4)
ab120652 は 4 報の論文で使用されています。
- Brown M et al. The differential effects of statins on the metastatic behaviour of prostate cancer. Br J Cancer : (2012). PubMed: 22531631
- Yap F et al. Mechanism of AMPK suppression of LXR-dependent Srebp-1c transcription. Int J Biol Sci 7:645-50 (2011). PubMed: 21647332
- Evangelopoulos ME et al. A role of nitric oxide in neurite outgrowth of neuroblastoma cells triggered by mevastatin or serum reduction. Neurosci Lett 468:28-33 (2010). PubMed: 19853642
- Wächtershäuser A et al. HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. Carcinogenesis 22:1061-7 (2001). PubMed: 11408350